Harnessing the Immune System against Osteosarcoma

by Katie Nightingale | Feb 2, 2023 | Research

In the last 30 years there has been very little change to osteosarcoma (OS) treatment. We are dedicated to changing this. Through the Myrovlytis Trust, we fund research into OS, with a focus on finding new treatments. We are pleased to announce we have awarded funding...

Testing Existing Drugs in Osteosarcoma Models

by Katie Nightingale | Nov 22, 2022 | Research

There is an urgent need to find new therapies in osteosarcoma (OS) that has spread or has not responded to standard treatment. Identifying new treatments can be a long and complex process. One method of speeding up the process is to use drugs that already approved to...

Using 3D Bioprinting to Study Osteosarcoma

by Katie Nightingale | Nov 15, 2022 | Research

There is a great need to develop new treatments for osteosarcoma (OS). This is particularly true for OS that has spread or has not responded to current standard therapy. Researchers are actively working towards finding new drugs to treat OS. To enable the drug...

Immuno UK Conference Report

by Katie Nightingale | Oct 18, 2022 | Research

In September 2022, we attended the Immuno UK conference. Held over 2 days in London, UK, this conference brought together over 260 people from industry and academic research. We heard the latest updates in the field of “immune oncology”. This can be described as...

Could P2 Receptors Be Targets For Primary Bone Cancer Therapy?

by Katie Nightingale | Sep 20, 2022 | Research

Primary bone cancer (PBC) is a group of cancers that includes osteosarcoma (OS). Other cancers in this group are Ewing’s sarcoma, chondrosarcoma and chordoma. There have been few advances in the treatment of PBC for the past 40 years. This means there is an urgent...